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DUET: A Phase 2 Study Evaluating the Efﬁcacy and
Safety of Sparsentan in Patients with FSGS
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Jonathan Hogan,10 Kenneth Lieberman,11,12 Brad Marder,13 Kevin Edward Meyers,14,15
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Vladimír Tesar,21,22 Olga Zhdanova,23 Radko Komers,24 and on behalf of the DUET Study Group

Due to the number of contributing authors, the afﬁliations are listed at the end of this article.

ABSTRACT
Background We evaluated and compared the effects of sparsentan, a dual endothelin type A (ETA) and
angiotensin II type 1 receptor antagonist, with those of the angiotensin II type 1 receptor antagonist
irbesartan in patients with primary FSGS.
Methods In this phase 2, randomized, double-blind, active-control Efﬁcacy and Safety of Sparsentan (RE-021),
a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Randomized, Double-blind, Active-Control, Dose-Escalation Study (DUET), patients aged
8–75 years with biopsy-proven FSGS, eGFR.30 ml/min per 1.73 m2, and urinary protein-to-creatinine ratio
(UP/C) $1.0 g/g received sparsentan (200, 400, or 800 mg/d) or irbesartan (300 mg/d) for 8 weeks, followed by
open-label sparsentan only. End points at week 8 were reduction from baseline in UP/C (primary) and proportion
of patients achieving FSGS partial remission end point (FPRE) (UP/C: #1.5 g/g and .40% reduction [secondary]).
Results Of 109 patients randomized, 96 received study drugs and had baseline and week 8 UP/C measurements. Sparsentan-treated patients had greater reductions in UP/C than irbesartan-treated patients
did when all doses (45% versus 19%; P=0.006) or the 400 and 800 mg doses (47% versus 19%; P=0.01) were
pooled for analysis. The FSGS partial remission end point was achieved in 28% of sparsentan-treated and
9% of irbesartan-treated patients (P=0.04). After 8 weeks of treatment, BP was reduced with sparsentan
but not irbesartan, and eGFR was stable with both treatments. Overall, the incidence of adverse events
was similar between groups. Hypotension and edema were more common among sparsentan-treated
patients but did not result in study withdrawals.
Conclusions Patients with FSGS achieved signiﬁcantly greater reductions in proteinuria after 8 weeks of
sparsentan versus irbesartan. Sparsentan was safe and well tolerated.
J Am Soc Nephrol 29: 2745–2754, 2018. doi: https://doi.org/10.1681/ASN.2018010091

Focal segmental glomerulosclerosis (FSGS)
encompasses a heterogeneous group of clinical
conditions with deﬁned glomerular histopathology.
Patients with FSGS typically present with a variable degree of proteinuria and often nephrotic syndrome.1,2
Primary FSGS has no identiﬁable cause but may be a
consequence of actions of putative circulating permeability factors that damage podocytes.1–5 FSGS
may be also a result of genetic abnormalities in
J Am Soc Nephrol 29: 2745–2754, 2018
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podocyte proteins.1–5 In contrast, secondary forms of FSGS are
caused by loss of renal parenchyma, metabolic derangements,
and other antecedent diseases, drugs, or infections.1 Disease
incidence is increasing, and in the United States, nearly 50%
of patients with primary FSGS and nephrotic-range proteinuria resistant to treatment will require RRTwithin 5–10 years of
diagnosis.6 FSGS accounts for 5% of adult and 12% of pediatric
patients with ESRD.7–9
Current treatment with corticosteroids or other immunomodulating agents is aimed at reducing proteinuria, an independent predictor of renal survival in patients with primary
FSGS. These agents are routinely combined with renin-angiotensin system inhibitors (RASIs).10–13 However, use of immunomodulating drugs is often hampered by therapy-limiting
side effects.9,12 As a result, the availability of effective and
safe, well tolerated drugs to reduce proteinuria is an unmet
medical need in primary FSGS.14
Endothelin type A (ETA) receptor antagonists have emerged as
promising therapies that may augment RASI actions.15 Preclinical
studies have shown that both endothelin (ET) and angiotensin II
(AngII) injure podocytes through several molecular mechanisms
and small-molecule endothelin receptor antagonists (ERAs) or
RASIs ameliorate parenchymal injury and reduce proteinuria in
rodent models of FSGS.16,17 In humans, the additive antiproteinuric beneﬁt from combining ERAs and RASIs was demonstrated
in diabetic nephropathy.15,18,19
Sparsentan is a ﬁrst-in-class, orally active, selective antagonist of
the angiotensin II type 1 (AT1) receptor and the ETA receptor.17,20
Here we report the outcomes from the double-blind treatment
period of the Efﬁcacy and Safety of Sparsentan (RE-021), a Dual
Endothelin Receptor and Angiotensin Receptor Blocker, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Randomized, Double-blind, Active-Control, Dose-Escalation Study
(DUET), a phase 2 study of the efﬁcacy and safety of sparsentan
compared with irbesartan, to reduce proteinuria in patients with
primary FSGS. The hypothesis of the DUET study was that dual
blockade of the AT1 and ETA receptors with sparsentan in patients
with primary FSGS would reduce proteinuria more than blockade
of the AT1 receptor alone (irbesartan).

METHODS

A complete description of the DUETstudy design has been published (Clinicaltrials.gov trial registration: NCT01613118).21
The DUET study, approved as an ancillary study by the Nephrotic Syndrome Study Network cohort study,22 enrolled patients at 44 sites between April of 2014 and April of 2016 in the
United States and Europe after institutional review board or
ethics committee approvals, in accordance with the Declaration
of Helsinki. The methodology is brieﬂy summarized below.
Patients

Eligible patients were aged 8–75 years in the United States and
18–75 years in Europe; all had biopsy-proven FSGS or a
2746
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Signiﬁcance Statement
Currently, no US Food and Drug Administration-approved therapies
are available for the treatment of primary FSGS. Sparsentan is a dual
endothelin type A (ETA) and angiotensin II type 1 (AT1) receptor
antagonist for oral administration. This article describes ﬁndings
from a phase 2, 8 week, randomized, double-blind trial of sparsentan versus an active comparator (AT1 receptor blocker irbesartan) in patients with primary FSGS. Patients achieved signiﬁcantly
greater reductions in proteinuria with sparsentan compared with
irbesartan over 8 weeks, without an increase in adverse events.
Thus, sparsentan may provide a new therapeutic option for reduction in proteinuria in patients with primary FSGS; additional
studies with longer follow-up are needed.

disease-causing genetic mutation associated with FSGS, urinary protein-to-creatinine (UP/C) ratio $1.0 g/g, and
eGFR.30 ml/min per 1.73 m2. Kidney biopsies were performed for clinical indications and processed for light microscopy, immunoﬂuorescence, and electron microscopy on the
basis of the availability of tissue for testing. The histologic
deﬁnition of FSGS was segmental obliteration of glomerular
capillaries by extracellular matrix in all cases. Entrapment of
plasma proteins as hyalinosis could accompany the sclerosis.
Adhesions, or synechiae, could be present between the sclerosing segment and Bowman’s capsule. On electron microscopy, the major ﬁnding was extensive effacement of the foot
processes without other abnormalities in the glomerular basement membrane. Immunoﬂuorescence could demonstrate
segmental staining for Ig M and C3 entrapped in areas of
hyalinosis.1 Secondary causes of FSGS were excluded at the
discretion of the investigator.
Immunosuppressive medications, except cyclophosphamide and rituximab, were permitted if dosing was stable for
1 month before randomization. The doses of these medications
were unchanged during the 8-week, double-blind treatment
period.
Study Design and Treatment

After providing informed consent or assent, patients were
screened to conﬁrm eligibility and, if necessary, underwent a 2week washout period to discontinue prescribed AngII-receptor
blockers or angiotensin-converting enzyme inhibitors. At week 0,
patients were randomized 3:1 through an interactive web response
system within sequential dose-escalating, 20-patient cohorts (Figure 1) to receive sparsentan 200, 400 (two cohorts), or 800 (two
cohorts) mg/d (Retrophin, Inc., San Diego, CA) or the active
control irbesartan 300 mg/d (Bristol-Myers Squibb Sanoﬁ-Synthelabo Partnership, New York, NY). Incremental safety reviews
were performed by an independent Data Monitoring Committee
(DMC). Initially, only patients aged $18 years were enrolled in
cohort 1 at the lowest sparsentan dose (200 mg). After eight
patients completed 4 weeks of treatment, the DMC
performed a safety review and enrollment was opened to patients
aged 8–17 years and cohort 2 was opened for randomization
of patients to receive sparsentan 400 mg or irbesartan 300 mg.
J Am Soc Nephrol 29: 2745–2754, 2018

www.jasn.org

CLINICAL RESEARCH

Figure 1. Patient disposition for the double-blind study period. The prespeciﬁed plan for allocation of patients to dose cohorts was
20–40–40 for 200–400–800 mg dose cohorts. The EES population included patients who received at least one dose of study drug and
had both baseline and week 8 UP/C assessments. Some patients received half of the assigned nominal dose owing to body wt#50 kg.
AE, adverse event; EES, efﬁcacy evaluable set; FAS, full analysis set.

The DMC repeated this process after eight patients completed 4
weeks of treatment at 400 mg, and again after eight patients
completed 4 weeks at 800 mg. DMC reviews continued every 6
months. Patients randomized to irbesartan received 150 mg/d for
the ﬁrst week before escalating to 300 mg/d for the remaining 7
weeks. Patients with body wt #50 kg received 50% of the assigned study drug doses.
Investigators, participants, caregivers, and the study sponsor
were blinded to treatment allocations until database extraction and
unblinding at the completion of the 8-week, double-blind treatment period. After completion of the double-blind treatment
period, patients could immediately continue to receive sparsentan
in an open-label treatment period for an additional 144 weeks.
The primary end point was change in UP/C ratio from baseline
to week 8. The secondary end point was the proportion of patients
who achieved the FSGS partial remission end point (FPRE), deﬁned as UP/C#1.5 g/g and a .40% reduction in UP/C from
baseline to week 8.23 Tertiary end points included changes from
baseline in BP, eGFR, and select laboratory parameters.
Safety and tolerability were assessed through adverse events
(AEs), including severity and relationship to study treatment,
physical examinations, and changes in laboratory parameters.
J Am Soc Nephrol 29: 2745–2754, 2018

Assessments

Peripheral blood/serum and urine samples were analyzed at a
central laboratory. For the primary end point analysis, UP/C
was measured in samples from 24-hour urine collections performed before study visits. eGFR was derived using the Modiﬁcation of Diet in Renal Disease formula for patients aged $18
years and the Schwartz formula for patients aged ,18 years.
BP was measured three times when patients were seated for
$5 minutes; the mean of the last two readings was recorded.
Statistical Analyses

Statistical analyses were performed using SAS version 9.4. The
full analysis set (FAS) was deﬁned as all randomized patients
who received at least one dose of study drug and had at least one
postbaseline efﬁcacy evaluation. The efﬁcacy evaluable set
(EES) included all patients who received at least one dose of
study drug and had both baseline and week 8 UP/C measurements. The safety analysis set included all randomized patients
who received at least one dose of study drug and had at least
one postbaseline safety evaluation. UP/C data were logtransformed before analyses to reduce skewness. Analysis of
covariance (ANCOVA) models were ﬁtted to the change
Sparsentan to Treat FSGS
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Table 1. Baseline demographics and characteristics (FAS)
Characteristics
Age, n (%)
Pediatric, $8 to #18 yr
Adult, .18–75 yr
Sex, n (%)
Female
Male
Race, n (%)
Asian
Black
White
Other
Ethnicity, n (%)
Hispanic/Latino
Non-Hispanic/non-Latino
Body mass index, kg/m2, mean (SD)
Immunosuppression at baseline, n (%)
eGFR, ml/min per 1.73 m2, mean (SD)
UP/C ratio, g/g, median (range)
ACE inhibitor or ARB use before washout, n (%)
Use of $1 diuretic/antihypertensive agent, n (%)
Diuretics
Additional antihypertensive treatments

Irbesartan
(n=36)

Sparsentan, All Doses
(n=73)

10 (28)
26 (72)

13 (18)
60 (82)

17 (47)
19 (53)

32 (44)
41 (56)

1 (3)
7 (19)
26 (72)
2 (6)

5 (7)
8 (11)
57 (78)
3 (4)

6 (17)
30 (83)
28.7 (6.4)
13 (36)
74.5 (44.7)
3.12 (0.9–10.7)
32 (89)
20 (56)
9 (25)
16 (44)

14 (19)
59 (81)
28.4 (6.1)
21 (29)
74.4 (37.3)
3.61 (0.4–18.7)
59 (81)
40 (55)
26 (36)
29 (40)

effect. The ratio comparing sparsentan
against irbesartan (i.e., [sparsentan week
8/sparsentan week 0]/[irbesartan week 8/
irbesartan week 0]) and the corresponding
95% CI are derived from back-transforming the appropriate contrast applied to the
estimates from the MMRM.
Safety data were summarized using descriptive statistics and evaluation of 95%
CIs.
In addition to descriptive statistics,
MMRM, which implicitly impute missing
data, were used for analyses of select tertiary
end points, namely BP and eGFR.

RESULTS
Patient Disposition and Demographic
Characteristics

The study screened 185 patients and enrolled 109 between April of 2014 and April
of 2016 (Figure 1) in the FAS, including 23
patients aged 8 to #18 years (inclusive)
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; eGFR, estimated glo(Table 1). Seventy three patients received
merular ﬁltration rate; FAS, full analysis set; SD, standard deviation; UP/C, urinary protein-to-creatinine
ratio.
sparsentan and 36 patients received irbesartan, of which 94% completed the double-blind period and 88% provided both
baseline and week 8 urine samples for determination of the
from baseline in natural log UP/C, with treatment and dose
primary end point.
cohort as main effects and the natural log of baseline UP/C as a
Baseline characteristics were similar between treatment
covariate. The treatment group geometric mean percent
change from baseline in UP/C at 8 weeks and the corresponding groups (Table 1), including proportion of patients receiving
RASIs before washout, as well as other antihypertensive agents
95% conﬁdence interval (95% CI) were calculated by back(excluding RASIs and diuretics), and immunosuppressive
transforming least squares means from the ANCOVA models.
treatment.
Treatment groups were compared using the ANCOVA models.
The prespeciﬁed plan for allocation of patients was 20–40–40
Sparsentan dose groups or their combinations were compared
for the 200–400–800 mg dose cohorts, with a 3:1 randomization
with irbesartan in the following prespeciﬁed hierarchical orof sparsentan to irbesartan within each cohort. The cohort alloder: (1) all sparsentan doses (800, 400, and 200 mg), (2) sparcation was achieved. After database extraction and unblinding, it
sentan 800 and 400 mg (combined), (3) sparsentan 400 mg,
was determined that the 3:1 randomization within cohorts was
and (4) sparsentan 800 mg.
not enforced. Therefore, a retrospective audit of the interactive
The proportion of patients achieving FPRE in each sparweb response system was arranged, which concluded that there
sentan dose group or their combination was compared with the
was an incorrect implementation of the intended randomization
proportion in the corresponding irbesartan group using the
Fisher exact test. Prespeciﬁed analyses were performed using plan. This error was not caught until the unblinding for the
interim analysis, as study blinding was maintained as planned.
data from patient subgroups of the EES population (Supplemental Material).
To address missing values, the EES was used for the analysis
Efﬁcacy
of the primary and secondary efﬁcacy end points. In a post hoc
There was a greater reduction in proteinuria among pooled (all
sensitivity analysis, change from baseline in natural log UP/C
doses combined) sparsentan-treated patients (244.8%; 95%
for 13 patients not included in the EES was imputed as zero. In
CI, 252.7% to 235.7%) compared with irbesartan-treated
addition, a post hoc mixed-model repeated measures
patients (218.5%; 95% CI, 234.6% to 1.7%; P=0.006; Figure
(MMRM) analysis was performed on the basis of FAS with
2A) after the 8-week, double-blind treatment period. Signiﬁthe natural log(UP/C) at week 0 (baseline) and week 8 as the
cantly greater reductions in UP/C from baseline to week 8
dependent variable, treatment, cohort, visit, and treatmentwere observed in the pooled higher-dose sparsentan groups
by-visit interaction as ﬁxed effects, and subject as a random (i.e., 400 and 800 mg) compared with the irbesartan group
2748
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(247.4% versus 219.0%; P=0.01; Figure
2B, Supplemental Table 1). Although the
trend was similar to that in the pooled
data analysis, the antiproteinuric effect of
individual sparsentan doses was not significantly different from that of irbesartan
(Supplemental Table 1). The results were
conﬁrmed by post hoc FAS analyses. The
results of the MMRM analysis are presented in Supplemental Table 2. The median
(range) UP/C calculated on the basis of the
FAS are similar to those calculated on the
basis of the EES. The ratio of UP/C week 8/
baseline for sparsentan is signiﬁcantly
lower than for irbesartan (ratio, 0.69;
P=0.01). These ﬁndings are consistent
with the primary analysis on the basis of
EES using ANCOVA. The results were
also conﬁrmed by analysis that imputed
zero change in proteinuria for 13 patients
who were missing baseline or week 8 data
(242.7% versus 215.7% reduction for all
doses; P=0.004; Figure 2C; 244.8% versus
215.9% reduction for 400 and 800 mg
doses; P=0.008; Figure 2D), as well as analysis of 24-hour urinary protein excretion in
the EES (255.1% versus 211.4% reduction for all doses; P=0.02; Figure 2E).
Overall, 28% of sparsentan-treated patients achieved FPRE compared with 9%
of irbesartan-treated patients (P=0.04;
Figure 2F, Supplemental Table 3). Although not a prespeciﬁed analysis, complete remission (UP/C,0.3 g/g) was
achieved during the 8-week, double-blind
period in three patients randomized to
sparsentan with one additional patient
reaching UP/C 0.3 g/g. No patients randomized to irbesartan achieved complete
remission.

Figure 2. Compared with irbesartan, there was a greater reduction in UP/C with
sparsentan, and a larger proportion of patients achieved FPRE. The ﬁgure illustrates
the reduction in UP/C from baseline to week 8 for (A) all sparsentan doses for the EES
and (B) 400 and 800 mg sparsentan doses for the EES. Reduction in UP/C from
baseline to week 8 for (C) all sparsentan doses for the FAS and (D) 400 and 800 mg
doses for the FAS. (E) Reduction in 24-hour urinary protein excretion for the EES.

J Am Soc Nephrol 29: 2745–2754, 2018

(F) Proportion of patients who achieved FPRE
for the EES. *Geometric least squares mean
percent change from baseline. P values for
changes in UP/C from analysis of covariance.
FPRE is deﬁned as UP/C#1.5 g/g and .40%
reduction in UP/C. P value for FPRE obtained
using the Fisher exact test. For the FAS analysis, patients with a missing UP/C value were
imputed as zero. EES, efﬁcacy evaluable set;
FAS, full analysis set; FPRE, FSGS partial remission endpoint; FSGS, focal segmental
glomerulosclerosis; UP/C, urinary protein-tocreatinine ratio.

Sparsentan to Treat FSGS
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ml/min per 1.73m2

in least squares mean change from baseline
at week 8 was –7.2 (95% CI, 211.8 to 22.6;
P=0.003) for systolic BP and 25.6 (95% CI,
29.0 to 22.2; P=0.002) for diastolic BP. A
signiﬁcantly greater hypotensive effect of
sparsentan was also observed in the pooled
analysis of data from the 400 and 800 mg
groups and the individual 800 mg sparsentan group compared with the irbesartan
group (P,0.05), albeit not in the individual
sparsentan 400 and 200 mg groups (data
not shown).
eGFR was similar between treatment
groups at baseline and remained stable for
sparsentan- and irbesartan-treated patients
Figure 3. Sparsentan had a greater effect on lowering BP compared with irbesartan, while
throughout the double-blind period (Figure
eGFR remained stable in both groups during the double-blind treatment period among patients in the EES. The ﬁgure illustrates the analyses of BP and eGFR on the basis of the efﬁcacy 3). From the MMRM model, the difference
evaluable set. eGFR on the basis of the Modiﬁcation of Diet in Renal Disease formula for pa- for sparsentan versus irbesartan in least
tients aged $18 years and Schwartz formula for patients aged ,18 years. Data were sum- squares mean change from baseline at week
marized using descriptive statistics and evaluation of 95% CIs. *P,0.05 compared with baseline. 8 was 24.2 (95% CI, 211.8 to 3.5; P=0.28).
**P,0.05 between treatment groups. BP, blood pressure; DBP, diastolic blood pressure; EES,
Serum concentrations of albumin and creefﬁcacy evaluable set; eGFR, estimated glomerular ﬁltration rate; SBP, systolic blood pressure; atinine, as well as liver function tests,
SD, standard deviation.
remained stable both in sparsentan- and irbesartan-treated patients and were similar in
Treatment with sparsentan had a greater effect on BP com- both groups. There was a trend toward increases in serum potaspared with treatment with irbesartan (Figure 3). From an
sium and decreases in hemoglobin and hematocrit concentrations
MMRM model, the difference for sparsentan versus irbesartan
among sparsentan-treated patients (Supplemental Table 4).
Table 2. Summary of treatment-emergent adverse events
during the double-blind period (FAS)
Patients, n (%)
AE

Overall incidence of TEAEs
Any
Drug-related
Serious
Leading to study withdrawal
Death
TEAEs with incidence .5%
Headache
Hypotension/orthostatic
hypotension
Dizziness
Edema/edema peripheral
Nausea
Diarrhea
Vomiting
Upper abdominal pain
Cough
Fatigue
Nasal congestion
Upper respiratory tract infection
Hyperkalemia
Muscle spasms

(n=36)

Sparsentan,
All Doses
(n=73)

26 (72.2)
13 (36.1)
1 (2.8)
1 (2.8)
0

56 (76.7)
32 (43.8)
2 (2.7)
2 (2.7)
0

7 (19.4)
3 (8.3)

14 (19.2)
12 (16.4)

4 (11.1)
1 (2.8)
3 (8.3)
1 (2.8)
1 (2.8)
2 (5.6)
2 (5.6)
4 (11.1)
4 (11.1)
2 (5.6)
2 (5.6)
2 (5.6)

10 (13.7)
9 (12.3)
9 (12.3)
6 (8.2)
6 (8.2)
4 (5.5)
3 (4.1)
3 (4.1)
2 (2.7)
2 (2.7)
1 (1.4)
0

Irbesartan

AE, adverse event; FAS, full analysis set; TEAEs, treatment-emergent adverse events.
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Safety

During the 8-week, double-blind period, the overall incidences
of treatment-emergent adverse events (TEAEs), drug-related
TEAEs, or serious TEAEs were similar between the sparsentan
and irbesartan groups (Table 2). The proportions of study
withdrawals because of TEAEs were also similar between treatment groups. No deaths occurred. Compared
with irbesartan-treated patients, sparsentan-treated patients
experienced more frequent hypotension, dizziness, edema,
and gastrointestinal TEAEs such as vomiting, diarrhea, and
nausea. In contrast, fatigue, nasal congestion, upper respiratory infections, muscle spasms, and hyperkalemia were more
common in the irbesartan-treated patients.
There were no signiﬁcant changes in severity of edema during the double-blind period (Table 3). There was no indication
of changes in body weight or N-terminal pro–B-type natriuretic peptide in either treatment group and no signiﬁcant
differences between groups (Supplemental Table 4). There
were also no meaningful between-group differences in overall
use and changes in diuretic treatment (Supplemental Tables 5
and 6), although loop diuretics were used more frequently in
sparsentan-treated patients than in irbesartan-treated
patients.
Subgroup Analyses

Although the trial was not powered for speciﬁc subgroup evaluation, analyses were performed to assess antiproteinuric
J Am Soc Nephrol 29: 2745–2754, 2018
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Table 3. Severity of edema during the double-blind period
(safety analysis set)
Edema
Severity
Grade
0
1+ to 2+
3+ to 4+

Patients, n (%)
Irbesartan (n=36)

Sparsentan, All Doses (n=73)

Baseline
(n=29)

Week 8
(n=28)

Baseline
(n=53)

Week 8
(n=60)

22 (76)
6 (21)
1 (3)

24 (86)
4 (14)
0

35 (66)
17 (32)
1 (2)

39 (65)
18 (30)
3 (5)

Outcomes compared using the Fisher exact test. No signiﬁcant differences
were identiﬁed.

effects of study drugs in patients stratiﬁed by factors associated
with progression of CKD, including age, race, severity of
proteinuria, CKD stage, sex, and presence or absence of hypertension (Supplemental Table 7). There were no statistically signiﬁcant
differences between treatment groups, although within-subgroup
observations suggest strong antiproteinuric effects of sparsentan.

DISCUSSION

The DUET study is the largest industry-sponsored, randomized, active-controlled trial in patients with primary FSGS
conducted to date. The ﬁndings indicate that short-term
dual blockade of the AT1 and ETA receptors with sparsentan
produced greater reduction in proteinuria than blockade of
the AT1 receptor alone. Treatment differences were statistically
signiﬁcant when combining all sparsentan doses and when
combining the two higher doses (400 and 800 mg). Moreover,
sparsentan was nearly three times as likely to achieve FPRE.
The antiproteinuric effect of sparsentan was observed in subgroups deﬁned by age, sex, proteinuria, baseline eGFR, and
baseline BP.
Dual AT1-ETA receptor blockade in proteinuric CKD has been
studied predominantly in diabetic nephropathy. These studies
showed additive effects of ERAs in patients with baseline treatment with RASIs.15,18,19 Experience with ERAs and dual blockade
in patients with nondiabetic CKD has been limited. Dhaun et al.24
reported additive effects on proteinuria with the ERA sitaxsentan
and RASI therapy in a 6-week study of patients with various primary and secondary nondiabetic glomerulopathies.
AngII and ET-1 affect practically all renal cell types.16,25,26
Overlaps in their pleiotropic actions may have additive effects in
the pathogenesis of FSGS, providing a strong rationale for dual
blockade.17 Enhanced efﬁcacy of sparsentan compared with irbesartan may reﬂect the enhanced protective effect on podocytes
speciﬁcally,24,27 and a spectrum of other nephroprotective antiﬁbrogenic, anti-inﬂammatory, and antioxidant actions.16,17
Although achieving remission in proteinuria has been
shown to be critical for the long-term preservation of kidney
function in patients with FSGS, the validity of short-term
changes in proteinuria as a surrogate of drug efﬁcacy in delaying/preventing ESRD is still debated.28 Moreover, limitations
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exist in the use of percentage reductions in proteinuria as an
index of drug efﬁcacy. To overcome these limitations, we used
FPRE, a novel surrogate end point in FSGS (UP/C reduction
by .40% to a value #1.5 g/g),23 as a meaningful treatment
outcome. As recently published, characterization of FPRE was
on the basis of analyses of ﬁve well-characterized databases of
patients with primary FSGS. Achievement of FPRE in response to a variety of treatments was associated with a significant improvement in renal outcomes compared with patients
who did not reach FPRE.23
The improvement in the FPRE rate observed with sparsentan in the double-blind phase of the DUET study suggests that
these are clinically meaningful changes in proteinuria with
regard to long-term renal outcomes. The ongoing open-label
treatment period of the DUET study will evaluate long-term
trends in kidney function in sparsentan-treated patients.
Very few serious AEs occurred in this study, and the frequencies were similar between treatment groups. Hypotension, dizziness, and headache were the most frequent TEAEs
in sparsentan-treated patients. One patient experienced a twofold increase in liver function tests that resolved completely
within 4 weeks of discontinuation of sparsentan. Other TEAEs,
such as fatigue, anemia, and hyperkalemia, were uncommon,
were mild to moderate in nature, and did not require study drug
discontinuation or study withdrawal. Although sparsentan
blocks two signaling systems, the TEAE proﬁle was not
additive.
Because ﬂuid retention was a major concern in previous
studies with selective ERAs,15,16,19 special attention was paid to
indices of ﬂuid retention in the DUET study. Edema-related
TEAEs were reported more frequently in sparsentan-treated
patients than in irbesartan-treated patients, and mild
decreases in hemoglobin or hematocrit were observed in sparsentan-treated patients, suggesting the possibility of hemodilution. Using a semiquantitative scale, we evaluated worsening
of edema and additional indirect indices of ﬂuid retention.
The proportion of patients receiving sparsentan with mild to
moderate edema remained stable, and the proportion with
severe edema rose from 2% to 5%. This occurred in parallel
with an increase in the use of loop diuretics. However, in nephrotic patients or patients with severe proteinuria, the etiology of edema is multifactorial; therefore, the contribution of
ET receptor inhibition to ﬂuid retention is difﬁcult to judge.
Patients entered the trial with varying degrees of edema reported as an AE. Moreover, there was no signiﬁcant change in
body weight or N-terminal pro–B-type natriuretic peptide
levels from baseline in sparsentan-treated patients. Importantly, no study withdrawals or serious AEs associated with
ﬂuid retention occurred. Altogether, during the double-blind
period, there were no serious safety signals of concern with
respect to ﬂuid retention.
Despite being one of the largest studies in FSGS, a limitation of
the DUETstudy was the number of patients enrolled in each dose
cohort. The study did not detect signiﬁcant differences in antiproteinuric effect between individual dose groups, potentially as a
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result of small sample sizes. Additionally, exclusion of patients
with missing data from the EES also limited the total number of
patients included in the analyses, particularly in the higher-dose
sparsentan and the irbesartan cohorts. Nevertheless, study patients were representative of the current population of patients
with FSGS,22,29 providing conﬁdence in the broad applicability
of the ﬁndings.
Unfortunately, a departure from the planned 3:1 randomization, caused by ﬂaws in the computerized randomization
procedures, led to a 2:1 ratio of sparsentan to irbesartan patients. These problems were not identiﬁed until treatment assignment was unblinded. Independent review conﬁrmed that
the study blind was maintained until after database extraction.
The total DUETstudy population included only 15 (14%) black
patients, thus offering limited opportunity for interpretation
of results in this patient subgroup with increased genetic risk
for, incidence of, and comorbidities associated with
FSGS.12,30,31 Additionally, no effect on eGFR could be detected
over the 8-week, double-blind treatment period but is being
studied in the ongoing open-label treatment period. Finally,
additional factors could have contributed to the greater antiproteinuric effect of sparsentan. These may have included
greater reduction in BP with sparsentan versus irbesartan,
which was observed in the study, and differences in sodium
intake, which were not assessed. Nevertheless, reductions in
BP stabilized within 2 weeks after initiation of study treatment. Moreover, available data from 68 patients who were
followed for 48 weeks in the open-label treatment period
demonstrate a steady rise in the percentage of patients who
achieved FPRE, reaching approximately 60% in patients originally randomized to either sparsentan or irbesartan. There
was further decline in UP/C during the open-label period that
was achieved without parallel changes in BP (data not shown).
Although the study had a high proportion of patients with
non-nephrotic-range proteinuria and consequently “mild”
FSGS with lower risk of progression to ESRD, many of these
patients had a history of overt nephrotic syndrome and were in
partial remission on immunosuppressive therapy. We suggest
that these patients would also beneﬁt from further reduction
of residual proteinuria. The favorable effect of sparsentan in
patients with nephrotic-range proteinuria indicates that drug
efﬁcacy is not limited to mild cases of primary FSGS (Supplemental Table 7).
Combining two pharmacologic effects in a single molecule
has the beneﬁt of reduction in pill burden and potentially
improved compliance. Moreover, dual blockade may create
synergy and improved efﬁcacy compared with agents that
block a single receptor. However, it would be premature to
conclude that dual receptor blockade is always superior to
single receptor blockade. It will be critical to verify the independent effects of each receptor blocker agent individually
before assessing the putative beneﬁt of a dual combined receptor blocking agent.
In conclusion, the results of the 8-week DUETstudy indicate
that dual blockade of the AT1 and ETA receptors by sparsentan
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($400 mg/d) reduces proteinuria signiﬁcantly more than single blockade of the AT1 receptor by irbesartan (300 mg/d) over
8 weeks of treatment in patients with primary FSGS. However,
long-term effects of sparsentan on preservation of kidney function remain to be determined. Sparsentan will be further evaluated in the DUET study open-label treatment period and, in
particular, in the phase 3 DUPLEX study (A Randomized, Multicenter, Double-Blind, Parallel, Active-Control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin
Receptor Blocker, on Renal Outcomes in Patients With Primary
FSGS; EudraCT number: 2016-005141-23; US ClinicalTrials.gov
identiﬁer: NCT03493685) to determine if it produces sustained
reduction in proteinuria and stabilizes kidney function compared
with AT1 receptor blockade without undue adverse effects. Positive ﬁndings from future, longer-term studies would represent a
major advance in the management of FSGS.
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